Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors

Abstract

Infliximab drug levels are associated with the depth of response/remission in patients with Crohn's disease, but no such relationship was observed for adalimumab. More data are needed to explain the variation in drug levels.